Combined morphologic-metabolic biomarkers from [18F]FDG-PET/CT stratify prognostic groups in low-risk NSCLC
Katharina Deininger, Joel Niclas Raacke, Elham Yousefzadeh-Nowshahr, Cornelia Kropf-Sanchen, Bernd Muehling, Meinrad Beer, Gerhard Glatting, Ambros J. Beer, Wolfgang Thaiss · Nuklearmedizin - NuclearMedicine · 2023 · Heft 05 · S. 284-292
Bibliografische Angaben
Zusammenfassung
Abstract Aim The aim of this study was to derive prognostic parameters from 2-[18F]fluoro-2-deoxy-D-glucose ([18F]FDG-PET/CT) in patients with low-risk NSCLC and determine their prognostic value. Methods 81 (21 female, mean age 66 a) therapy-naive patients that underwent [18F]FDG-PET/CT before histologic confirmation of NSCLC with stadium I and II between 2008–2016 were included. A mean follow-up time of 58 months (13–176), overall and progression free survival (OS, PFS) were registered. A volume of interest for the primary tumor was defined on PET and CT images. Parameters SUVmax, PET-solidity, PET-circularity,…
